SCOLR Pharma Prepares to Initiate Two Trials

SCOLR Pharma has announced that the FDA will permit U.S. testing of its 12-hour extended-release ibuprofen tablets.

The study will be used to support a new drug application, which the company plans to submit later this year. The company also confirmed its intention to initiate bioequivalency testing of its extended-release pseudoephedrine tablets to support an anticipated abbreviated new drug application expected to be submitted this summer.

Both products are designed for the U.S. OTC market and are based on the company's controlled delivery technology platform.